<DOC>
	<DOCNO>NCT00333138</DOCNO>
	<brief_summary>This study evaluate safety , tolerability effect MRI lesion parameter FTY720 patient relapse multiple sclerosis .</brief_summary>
	<brief_title>Efficacy Safety FTY720 Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Core Study Diagnosis relapse multiple Sclerosis ( MS ) Patients least two documented relapse previous 2 year one document relapse last year Patients Expanded Disability Status Scale ( EDSS ) score 06 Extension Study A positive Gdenhanced MRI scan screening ( case first MRI scan obtain screen negative , second scan could obtain 1 month later ) Neurologically stable evidence relapse within 30 day prior randomization , Screening Baseline period . Female patient either postmenopausal , surgically incapable bearing child , practice acceptable method birth control . Females childbearing potential negative pregnancy test baseline prior entry treatment period . Core Study Patients chronic disease immune system , malignancy , pulmonary heart disease , etc Pregnant nursing woman Extension Study Patients permanently discontinue study drug prior Month 6 visit core study Patients diabetes mellitus ( reduce risk ME ) , therefore ongoing patient diabetes mellitus develop diabetes mellitus discontinue study ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>FTY720</keyword>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>RRMS</keyword>
</DOC>